Semma Therapeutics: Vertex adds to deal spree with $950m for biotech seeking diabetes cure
Vertex is set to acquire Semma, which is developing a stem cell curative treatment for type 1 diabetes and expects the deal to ârapidly advanceâ its potential therapy.
Read full article »
Semma Therapeutics is a biotechnology company that develops and commercializes stem cell-based therapies for the treatment of diabetes.
Read more